Akoustis Technologies, Inc. is gearing up for a significant milestone as it prepares to go public on the NASDAQ, with plans to offer 17.65 million shares priced between $16 and $18. This strategic move is aimed at raising substantial capital, positioning Akoustis alongside other tech sector giants. Specializing in the development of advanced RF filter solutions for the wireless industry, Akoustis is set to compete with leading firms such as Qorvo and Broadcom.
Similarly, Aktis Oncology, a clinical-stage oncology company, has successfully priced its upsized U.S. initial public offering at $18 per share, raising approximately $318 million, as reported by GlobeNewswire. Offering 17.65 million shares, with an option for underwriters to purchase an additional 2.65 million shares, Aktis mirrors Akoustis' approach in share volume.
Aktis Oncology's IPO is slated to begin trading on the Nasdaq Global Select Market under the ticker symbol "AKTS" on January 9, 2026, with the offering expected to close on January 12, 2026, subject to customary closing conditions. This timeline offers a blueprint for Akoustis as it navigates its own journey to becoming a publicly traded entity on the NASDAQ.
The current stock price for NASDAQ:AKTS stands at $0.03, marking a 100% increase. The stock has experienced both its low and high at $0.03 for the day, with a market capitalization of approximately $5.76 million. A trading volume of 74,784,722 shares indicates robust investor interest, setting a precedent for Akoustis as it steps into the public market.
